Defects of metabolic enzymes result in a variety of manifestations not logically explained by the primary metabolic function. Dominant defects of fumarate hydratase (FH) result in predisposition to cutaneous and uterine leiomyomas, and renal cell cancer. FH is a metabolic enzyme of the tricarboxylic acid cycle, and its tumorsuppressor mechanism is not fully understood. We compared the consequences of FH deficiency and respiratory chain (RC) deficiency using global expression pattern of diploid primary fibroblasts. This approach utilized the information that RC defects do not seem to predispose to tumorigenesis, and the aim was to identify FH-specific signaling effects that might have relevance to tumor formation. These results were then compared to global expression patterns of FH-deficient and sporadic uterine leiomyoma data sets. We show here that FH-deficient fibroblasts share a common transcriptional fingerprint with FH-deficient and sporadic leiomyomas, highlighting the downregulation of serum response factor (SRF)-regulated transcripts, particularly the FOS-JUNB pathway. We confirmed the downregulation of this pathway at transcriptional and protein level. SRF has a fundamental function in the differentiation of smooth muscle progenitor cells, and its downregulation both in diploid FH-deficient primary fibroblasts and in leiomyomas suggests an early function in the mechanism of uterine leiomyoma formation in FH deficiency. Concordantly, the phosphorylated form of SRF, known to activate transcription, is undetectable in leiomyomas whereas clearly detected in several nuclei in the differentiated myometrium. A similar transcriptional SRFpathway fingerprint in FH-deficient and sporadic leiomyomas emphasizes the potential importance of this pathway in primary events leading to leiomyomatosis.
Introduction
Uterine fibroids, leiomyomas, are the most common tumors of the female reproductive tract, and a common cause of hysterectomy (Walker and Stewart, 2005) . Characterization of simple Mendelian traits associated with leiomyomatosis has revealed molecular pathogenic routes leading to these benign tumors: mutations in fumarate hydratase (FH), a key metabolic enzyme, cause genetic predisposition to leiomyomatosis (Tomlinson et al., 2002) .
Mitochondrial energy metabolism generates most of the cellular ATP. The machinery involved in this process includes the tricarboxylic acid (TCA) cycle and the respiratory chain (RC). Recessive defects of mitochondrial energy metabolism usually cause severe neurological or multisystem diseases that may lead to infantile death (Rustin et al., 1997) . However, heterozygous defects in FH and succinate dehydrogenase subunits B, C and D, enzymes that catalyse sequential steps of the TCA cycle, predispose to tumor formation (Baysal et al., 2000; Tomlinson et al., 2002) . FH defects lead to hereditary leiomyomatosis and renal cell cancer, and have been reported in other tumors, such as ovary adenocarcinomas, Leydig cell tumors and cerebral cavernomas (Tomlinson et al., 2002; Alam et al., 2003; Carvajal-Carmona et al., 2006; Ylisaukko-Oja et al., 2006; Campione et al., 2007; Refae et al., 2007) . Several hypotheses have been proposed for the mechanisms how FH deficiency leads to tumor formation, including fumarate accumulation inducing a hypoxic response, oxidative stress and decreased differentiation of FHdeficient progenitor cells (Eng et al., 2003; Pollard et al., 2003; Gottlieb and Tomlinson, 2005; Raimundo et al., 2008) . However, the primary cellular signaling consequences of FH deficiency in diploid cells and the mechanisms how those lead to tumor formation remain unknown.
We compared the consequences of FH and RC deficiencies to global transcriptional profile in primary diploid fibroblasts. RC defects caused by mitochondrial DNA (mtDNA) or by nuclear gene mutations affecting RC do not associate with predisposition to tumorigenesis; a vast literature describes RC defects in a variety of neurological phenotypes (Schapira, 2006; Smeitink et al., 2006) . Furthermore, genetically modified mice with large-scale accumulation of mtDNA mutations do not show increased tumorigenesis (Trifunovic et al., 2004; Tyynismaa et al., 2005) . Therefore, we hypothesized that the pathways that are common to RC and FH defects are likely to be consequences of defective oxidative ATP production, and not related to tumor predisposition. This allowed us to identify expression patterns specific to FH deficiency in diploid fibroblasts. These were compared to data sets from FH-deficient and sporadic leiomyomas. Integration of these data enabled us to determine the pathways that are specifically dysregulated early in diploid cells with FH deficiency, and also in uterine leiomyomas. We observed downregulation of serum response factor (SRF) signaling, which has a key function in smooth muscle differentiation (Pipes et al., 2006) , and suggest a role for loss of SRF signaling in uterine leiomyoma formation in FH-deficient patients and possibly also in common leiomyomagenesis.
Results
We focus here in FH deficiency and its specific consequences to global expression pattern and cell signaling in primary diploid fibroblasts, and compare these identified changes to those in sporadic and FHdeficient leiomyomas (Hoffman et al., 2004; Vanharanta et al., 2006) . Table 1 summarizes the various data sets used.
FH deficiency in primary diploid fibroblasts First, we studied the consequences of FH and RC deficiency for global expression patterns of primary diploid fibroblasts from two patients carrying recessive defects of FH ('FH fibroblasts' from now on) and one patient with RC defect, MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes; B80% mtDNA with T3271C mutation; 'MELAS fibroblasts' from now on). We hypothesized that the key signaling consequences that are relevant for tumor initiation events should be at least partially specific for FH deficiency, because RC deficiencies caused by mtDNA defects, such as MELAS, do not cause tumor predisposition. Figure 1 illustrates the analysis strategy. Those transcripts that were either statistically significantly different (Po0.05) or with a fold change >1.5 in FH (or MELAS) compared to the control fibroblasts were selected for further analysis. Altogether, the expression of 3163 transcripts was changed in FHdeficient fibroblasts compared to controls. Of these, 2499 transcripts were FH specific (Supplementary Table  1) , and 664 were similarly affected in FH deficiency and in MELAS (data not shown).
The expression of several FH-specific transcripts showed large fold changes (over 5-to 10-fold) in FH fibroblasts compared to controls in the expression array experiment (Table 2) . We validated some of these data using quantitative real-time PCR (Q-PCR). The correlation of the Q-PCR results with the microarray data was strong (R 2 >0.6) for 10 out of 11 transcripts studied (Supplementary Figure 1) . The expression array analysis was done for two FH-deficient fibroblast lines (FH-2 and FH-3) with two replicates. For Q-PCR verification, we included the samples from two additional FHdeficient primary fibroblasts as well as from an additional RC-deficient fibroblast line, NARP (neuropathy, ataxia, retinitis pigmentosa; B90% mtDNA with T8993C mutation). In Q-PCR, we observed that the expression level of the majority of the single transcripts with large fold-changes was not similarly changed in all FH-deficient fibroblast lines, possibly reflecting the different genetic background of the samples, and rendering it unlikely that they have a major function in general consequences of FH deficiency (Figure 2 ). Myocardin and placental growth factor (PGF), however, were dysregulated in all the FH-deficient fibroblasts. The conclusion of the Q-PCR confirmation was that the array results were readily replicated by an independent method, and therefore robust.
To increase biological insight, we studied which general pathways were affected in FH-deficient fibroblasts. The most significantly affected pathway in FHdeficient fibroblasts was the aryl-hydrocarbon receptor signaling (P ¼ 1.1 Â 10 À6 ; Supplementary Table 2) including retinoic acid receptor downregulation (P ¼ 0.027). This pathway is known to be involved in ) were also affected in FH deficiency in fibroblasts. General downregulation of the RC was specific for FH deficiency in fibroblasts, with decreased levels of several subunits of complex I (NDUFA3, NDUFA7, NDUFA8, NDUFA10, NDU-FA12, NDUFA13, NDUFB6, NDUFB7, NDUFB8, NDUFB10 and NDUFS7), complex III (UCRC, UQCRH and UQCRQ) and complex IV (COX4I1, COX4I2, COX6A1 and COX7C). Furthermore, other pathways involved in regulation of cell proliferation and survival were also affected in FH fibroblasts, with patterns indicating upregulation of PI3K/Akt/IKK cascade (P ¼ 7.8 Â 10 À3 , PTEN signaling, P ¼ 5.8 Â 10 À3 ), G 1 /S (P ¼ 7.8 Â 10 À6 ) and G 2 /M (P ¼ 0.042) cell-cycle checkpoints and glutathione synthesis (oxidative stress; P ¼ 2.3 Â 10 À3 ) (Supplementary Table 2 ).
SRF-FOS-JUNB pathway is downregulated in FH deficiency and in leiomyomas
We hypothesized that some pathways specific for FH deficiency should participate in the process of leiomyoma formation, because energy metabolic defects are not generally predisposing to tumors. Furthermore, fundamental pathways of mitochondrial metabolism are well conserved in different cell types, but diverse mechanisms of interpretation of signals may underlie the tissue-specific manifestations. Therefore, we compared the findings in primary diploid FH-deficient fibroblasts with several previously published data sets: GSE2724 and GSE2152 (Gene Expression Omnibus repository) included samples from normal myometrium, non-FH-deficient sporadic leiomyomas, inherited FHdeficient leiomyomas and sporadic FH-deficient leiomyomas (Vanharanta et al., 2006) (data set summary in Table 1 ).
We first asked whether the same transcripts were affected in FH-deficient fibroblasts and leiomyomas. Transcripts with significant expression differences (Po0.05) between inherited FH leiomyomas and wildtype myometrium, changing to same direction were considered (see Figure 1 for analysis strategy), and 145 transcripts were identified to be similarly changed in FH fibroblasts and leiomyomas. The full list of 145 transcripts is presented in Supplementary Table 3. This list was further used for Ingenuity Pathway Analysis to study specific coregulated transcriptional networks (detailed signaling networks based on specific handcurated information on protein-protein interactions).
In the network analysis of the 145 transcripts common to FH fibroblasts and leiomyomas, the most striking effect was observed with the FOS-JUNB network (P ¼ 1 Â 10
À35
). We chose to study further this network, as it showed the highest number of known direct regulatory interactions between the transcripts/ proteins, compared to the other networks (Table 3 ). The core network is illustrated in Figure 3a , and the full network transcript list with fold changes is summarized in Table 4 both for FH fibroblasts and leiomyomas. Individual transcripts FOS (fold change À3.73) and JUNB (fold change À1.64) were downregulated both in FH-deficient fibroblasts and in inherited FH leiomyomas. FOS and JUNB are so-called 'immediate-early genes', transcriptional targets of the same transcription factor, SRF, which was also downregulated in FHdeficient fibroblasts (fold change À1.3, P ¼ 0.017; Supplementary Table 1) . Furthermore, we found widespread downregulation of other known SRF targets; for example, myometrial smooth muscle a-actin (ACTA2 Figure 1 Microarray analysis strategy. (a) In the first step of the microarray data analysis, those transcripts that were similarly changed both in fumarate hydratase (FH) and in MELAS fibroblasts, compared to control fibroblasts, were removed (including putative common responses to oxidative ATP production defect). This resulted in selection of 2499 transcripts that were specifically changed in FH deficiency. (b) In the second step, the 2499 FH-fibroblast-specific transcripts were compared to those changed in FHdeficient leiomyomas (from the GSE2724 and GSE2152 data sets, GEO repository). Those 145 transcripts that were similarly changed in FH-deficient fibroblasts and leiomyomas constituted the working gene list.
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fold change À1.9), cardiac muscle a-actin (ACTC, fold change À4.7), myosin light chain 5 (fold change À1.8) and dystrophin (fold change À6.7) in FH fibroblasts (Supplementary Table 1 ). Dystrophin was also downregulated in MELAS (not shown).
To determine if the downregulation of FOS, JUNB and their functional partners was specific for FHdeficient leiomyomas or a general feature of leiomyomas, we performed hierarchical clustering according to the full FOS-JUNB network (Table 4) in all the available fibroblast, leiomyoma and myometrium data sets. Interestingly, a specific heatmap fingerprint for this network could be identified (Figures 3b-d and f)-the inherited FH-deficient leiomyomas, sporadic FH-deficient leiomyomas, non-FH-leiomyomas and FH fibroblasts showed a common expressional fingerprint concerning this network, and mostly clustered together. Furthermore, the result was replicated using another leiomyoma/myometrium data set (GEO repository, GDS 484) (Hoffman et al., 2004) (Figure 3e ). In particular, the downregulation of FOS and JUNB in leiomyomas was observed in both data sets, regardless of the FH status of the leiomyomas (Figures 3b-e) . The downregulation of SRF transcriptional targets is therefore a common feature linking FH deficiency in primary cultured fibroblasts with the formation of smooth muscle tumors in FH deficiency, and leiomyoma formation in general, regardless of FH activity. Fold change calculated as average of the FH samples (n ¼ 4) divided by the average of the control samples (n ¼ 4).
Phospho-SRF is decreased in FH-deficient primary fibroblasts and in leiomyomas We used Q-PCR and western blot analysis to confirm the array results for SRF in FH-deficient fibroblasts ( Figure 4, Supplementary Figure 1) . The downregulation of SRF transcript levels was observed in all FH samples (Figure 4a ), using (GAPDH) transcript levels as a control (b-actin transcript as another control gave similar results as GAPDH, not shown). Phosphorylation of SRF (SRF-P) is known to modulate its ability to bind to the serum response element (SRE) of c-Fos promoter (Janknecht et al., 1992) , thereby regulating c-fos transcription (Rivera et al., 1993) . By western blot, SRF-P (Ser-103) was decreased in FH-deficient primary fibroblasts, and the amount of SRF-P correlated with the decreased transcript and protein levels of FOS ( Figure 4b ). The transcript levels of FOS and JUNB were significantly downregulated in FH-deficient fibroblasts, whereas they were induced (FOS) or unchanged (JUNB) in MELAS and NARP (Figure 4a ). SRF can be phosphorylated at multiple sites in the C-terminal region. To study if the phosphorylation of Ser-103 correlated with transcriptional activity of SRF, we serum-deprived the cells for 24 h, and then allowed them to recover for 2 h in normal growth medium. The transcriptional levels of Fos decreased sharply after serum deprivation, but increased after 2 h in normal growth medium (Figure 4c ). The SRF-P levels followed a similar pattern (Figure 4c ), suggesting a correlation between SRF (Ser-103) phosphorylation Figure 2 The quantitative PCR analysis of transcripts with largest significant fold changes in microarray experiment. For each sample, the average of minimally four replicate results was plotted ( ± standard deviation). When the three controls had disparate expression values, they were represented individually. At least four independent quantitations were performed per transcript per sample. Statistically significant changes are marked: *Po0.05, **Po0.01 and ***Po0.001. FH-1, fumarate hydratase-deficient patient sample, E362Q homozygote; FH-2, Q376P homozygote; FH-3, compound heterozygote InsK477/R233H; FH-4, compound heterozygote with delV387 þ Q386H/P369S; MELAS, fibroblasts from a patient with mutation T3271C (B80% mutated mtDNA); NARP, sample with T8993C (B90% mutated mtDNA).
and Fos transcriptional regulation. To study the presence of phosphorylated SRF (Ser-103) in leiomyomas, we performed immunohistochemistry in paraffinembedded sections of myometrium and FH-deficient and sporadic leiomyomas for SRF-P. As shown in Figure 5 , the myometrium displays nuclear signal for SRF-P, whereas virtually no signal is detected in the leiomyomas. 
1EÀ26
Glucocorticoid receptor network kABCA1, kCASP9, mCHEK1, m FKBP4, kFNTA, kGNAZ, mHSPA5, kLMO4, kNR1H3, kNR3C1, kPROS1, kRGS2, kTEK, kTRPC4
1E-24
TNF network mC1QBP, mDKK2, kGALC, kGLS, kGLTSCR2, kJUNB, kKCNJ8, kPABPC4, kPCSK5, mPRDX6, kSKP1A, mTNFRSF21, kTSC22D3, kZFP36
1EÀ24
Retinoic acid receptor network kATP6V1E1, kCHMP4A, kDHRS3, kDSTN, kJUNB, kPDCD4, kPLCE1, mRAP1GDS1, kRNASE4, kSERPING1, kSLC19A2, mSLC5A3, kSPON1, kTCF7L2
TGF-b network kCMAH, kDAZAP2, kDLG5, mKPNB1, kLTBP1, kMCCC1, mNCAPG, kPCOLCE2, kPKNOX1, mPLOD2, kRANBP5, m RCC1, mSMN1
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Progesterone network mAHCYL1, kAQP1, kAVPI1, kCOX7C, kGRAMD3, kJAG1, kJUNB, mME1, kMFAP5, kPCBD1, mTKT, kTNS1
1EÀ19
The transcripts, the expression of which was similarly affected in FH fibroblasts and in inherited FH leiomyomas, were grouped into functional networks based on Ingenuity Pathway Analysis Software (hand-curated databank for specific published protein interactions and specific regulatory networks). The arrows show the direction of the change, up-(m) or downregulation (k) in FH fibroblasts and leiomyomas. Table 4 .
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Discussion
We report here transcriptional consequences of FH deficiency, a metabolic defect associated both with severe infantile encephalopathies and with inherited tumor predisposition (Tomlinson et al., 2002; Alam et al., 2003; Carvajal-Carmona et al., 2006; YlisaukkoOja et al., 2006; Campione et al., 2007; Refae et al., 2007) . We searched for FH-deficiency-specific transcriptional networks comparing FH deficiency to RC deficiencies, the latter being not linked to increased risk for tumorigenesis. The FH-specific networks identified in primary fibroblasts were then tested in FH-deficient leiomyoma transcriptome data sets, to study the relevance of fibroblast data to leiomyoma formation. Although FH-deficient fibroblasts were diploid with normal growth behavior (Raimundo et al., 2008) , but showed low FH activity similar as FH-deficient leiomyomas, networks common to these cells and leiomyomas are excellent candidates to be involved in FHrelated leiomyoma formation. We show here that FHdeficient fibroblasts and leiomyomas show widespread downregulation of the SRF-regulated transcripts and also of active SRF, known to participate in smooth muscle cell differentiation (Pipes et al., 2006) . This downregulation was common also to sporadic leiomyomas with no known link to FH defect. SRF-regulated FOS-JUNB network inhibiting smooth muscle cell differentiation may have a key function in primary events in leiomyoma formation. SRF is a transcription factor crucial for differentiation of smooth muscle progenitor cells to functional smooth muscle cells (Pipes et al., 2006) . It is also involved in the formation of embryonic mesoderm, from which the smooth muscle tissue arises (Arsenian et al., 1998; Weinhold et al., 2000) . SRF binds to cis-elements known as SREs in the promoter regions of several genes (Chai and Tarnawski, 2002) . These include so-called 'immediate-early genes' c-FOS and JUNB. These transcripts were downregulated in FH fibroblasts, as well as other SRF target genes, such as smooth muscle a-actin, keratins, cardiac muscle a-actin and dystrophin (Catala et al., 1995; Marshall et al., 2001; Carlini et al., 2002; Kelm et al., 2003; Du et al., 2004; Parlakian et al., 2004; Zhang et al., 2005; Balza and Misra, 2006) . SRF-P Ser-103, which is controlled by multiple pathways, Values represent the fold change of each group versus the respective control (normal fibroblast controls for patient fibroblast lines and normal myometrium for leiomyoma samples). The fold change for downregulated transcripts is marked as negative. Groups as described in Table 1 .
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including CamKIV, ERK-Rsk and MK2 signaling (Rivera et al., 1993; Misra et al., 1994; Heidenreich et al., 1999) , was significantly lowered in FH cells as well as in leiomyomas. Of SRF target genes in FHfibroblasts, both immediate-early genes and transcripts encoding structural proteins were downregulated, whereas in FH-deficient leiomyomas only immediateearly genes were downregulated. Interestingly, a similar pattern of downregulation of immediate-early SRF targets was also verified in FH-deficient leiomyomas as well as in sporadic leiomyomas. Decreased expression levels of FOS and JUNB in leiomyomas were previously reported (Hoffman et al., 2004; Shozu et al., 2004; Arslan et al., 2005) . Although it remains unclear whether or how SRF Ser-103 phosphorylation contributes to activation of SRF target genes, our data strongly suggest that FH-induced alterations in signaling result in reduced FOS-JUNB network expression. The formation of leiomyomas due to decreased differentiation of smooth muscle progenitors was previously suggested (Arslan et al., 2005) . The downregulation of SRF signaling described here is concordant with such a model for leiomyoma formation, because SRF is well known to be important for smooth muscle differentiation. However, our findings suggest that FOS and JUNB might be involved in smooth muscle differentiation through regulation by SRF.
Previous studies have identified a specific transcriptional signature of FH-deficient leiomyomas distinct from sporadic leiomyomas (Vanharanta et al., 2006) , including strong upregulation of glycolysis, and discussed the contribution of Warburg effect to tumorigenesis. Upregulation of glycolysis is a logical consequence of downregulation of the oxidative ATP production pathway due to the lack of the activity of a key metabolic enzyme FH. FH-deficient leiomyomas have also been shown to activate hypoxia response through HIF1-a pathway induction (Eng et al., 2003; Pollard et al., 2003 Pollard et al., , 2005a Pollard et al., , b, 2007 Isaacs et al., 2005) . The transcripts associated with hypoxia response were, however, only induced in FH-deficient leiomyomas, but not in sporadic leiomyomas or fibroblasts with FH deficiency or MELAS (Vanharanta et al., 2006) . We have previously shown that reduced redox environment, possibly linked to increased fumarate accumulation, associated with decreased differentiation, is specific for FH deficiency (Raimundo et al., 2008) . FH-deficiency- Western blot analysis for SRF-P and FOS, using nuclear extracts from fibroblast cell lines, and MAT1 as a loading control. (c) Effect of serum depletion and repletion on FOS transcriptional levels and in SRF Ser-103 phosphorylation. The statistical comparisons performed were of each line after depletion, compared to the normal value, and after repletion, compared to the respective depletion value. Values in the graphs represent averages±standard deviation of at least three independent experiments. Statistically significant changes are marked: *Po0.05, **Po0.01 and ***Po0.001. FH-1, fumarate hydratase-deficient patient sample, E362Q homozygote; FH-2, Q376P homozygote; FH-3, compound heterozygote InsK477/R233H; FH-4, compound heterozygote with delV387 þ Q386H/P369S; MELAS, fibroblasts from a patient with mutation T3271C (B80% mutated mtDNA); NARP, sample with T8993C (B90% mutated mtDNA).
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N Raimundo et al related Warburg effect and HIF induction could enhance proliferation and contribute to tumor growth and progression in the smooth muscle progenitors, in which redox environment is reduced and SRF signaling is downregulated thereby inhibiting differentiation. We suggest that this smooth muscle differentiation defect might underlie general leiomyoma formation, and that FH-specific metabolic changes with Warburg effect and hypoxia pathway induction would contribute to the secondary progression of tumors and lead to the exceptional multiplicity and large tumor size often associated with the leiomyomatosis caused by FH deficiency.
The network analysis carried out in this study highlighted other signaling hubs that are potentially relevant for leiomyoma formation, such as b-estradiol, tumor necrosis factor-a (TNF-a), retinoic acid pathway, transforming growth factor-b (TGF-b) and progesterone receptor. However, contrary to the SRF-FOS network, most of these did not present overall consistency, some targets of a pathway being upregulated and others downregulated. The glucocorticoid receptor (GR) hub, however, showed some consistency. Three transcriptional targets of GR (Mittelstadt and Ashwell, 2003; Phuc Le et al., 2005) appeared downregulated in FH deficiency and in leiomyomas (ABCA1, FNTA and LMO4), and GR expression was downregulated. GR is a known repressor of stem cell number and proliferation (Chebotaev et al., 2007) , and has been reported to be downregulated in leiomyomas (Wei et al., 2005) . Downregulation of GR signaling may thus contribute to lower differentiation phenotype in FH smooth muscle cells and to the formation of the leiomyomas.
In conclusion, we identified common transcriptional signatures both in FH-deficient primary fibroblasts and leiomyomas. Among several networks that were affected by FH deficiency, the SRF-FOS-JUNB network was similarly affected in leiomyomas from FHdeficient and non-FH patients. SRF is a known key regulator of smooth muscle progenitor differentiation, and we suggest here that FOS and JUNB are involved in this differentiation. The primary lack of differentiation signals through reduced SRF signaling may be a common denominator in leiomyomagenesis. SRF-FOS-JUNB pathway in myomas N Raimundo et al FH-deficiency-associated leiomyomas are usually more numerous and larger than sporadic myomas, which may be due to lack of oxidative ATP production and consequent glycolysis induction, as well as hypoxia pathway activation, boosting proliferation in the formed leiomyoma seeds. Induction of SRF signaling is a possible target to block primary leiomyoma formation.
Materials and methods
Leiomyomas
The leiomyoma and myometrium specimens were either anonymous (myometrial samples, n ¼ 1; sporadic leiomyomas, n ¼ 2) or analysed after obtaining informed consent (FHdeficient tumors, n ¼ 2). The study has been approved by the appropriate ethics review boards.
Cells
All skin samples for fibroblast culture were taken with informed consent, according to The Helsinki Declaration. The patient cell lines have been described in detail in Raimundo et al. (2008) . In short, four FH-deficient fibroblast lines from patients with recessive FH deficiency were used-FH-1, homozygous for the E362Q mutation (Bourgeron et al., 1994) ; FH-2, homozygous for the Q376P mutation (Remes et al., 2004) ; FH-3 is a compound heterozygote with InsK477/ R233H (Loeffen et al., 2005) ; and FH-4 is a compound heterozygote with delV387 and Q386H changes in one allele, and P369S in the other (Maradin et al., 2006) . (These lines were kind gifts from Pierre Rustin (Bourgeron et al., 1994) , Jan Smeitink (Loeffen et al., 2005) , Anne M Remes (Remes et al., 2004) and Ksenija Fumic´, Ivo Baric´ (Maradin et al., 2006) .) The residual FH activities in these lines were o1% for FH-1, o0.5% for FH-2, 20% for FH-3 and 5% for FH-4 (Bourgeron et al., 1994; Remes et al., 2004; Loeffen et al., 2005; Maradin et al., 2006) . The RC-deficient lines were from an 18-year-old female patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like-episodes syndrome (MELAS) due to a T3271C mutation in tRNA-leucine of mtDNA, with B80% of mutant mtDNA, and from a 3-year-old patient with neurogenic muscle-weakness ataxia and retinitis pigmentosa syndrome (NARP), due to the T8993C mutation in mtDNA with B90% mutant mtDNA. Control fibroblasts were from an adult, a child of 5 months of age and the third from a 1-yearold child. None of the controls had signs of a metabolic disease.
Cell culture Cells were cultured in Dulbecco's modified Eagle's medium with 4.5 g/l glucose and 2 mM L-glutamine, supplemented with 10% fetal bovine serum (FBS), uridine 50 mg/ml, penicillin 100 U/ml and streptomycin 100 mg/ml, at 37 1C in the presence of 5% CO 2 . All cell culture reagents from Gibco-Invitrogen (Carlsbad, CA, USA). For experimental purposes, the cells used were between passages 10 and 20.
For the serum-starvation experiment, the cells received 0.5% FBS for 24 h. Some samples were harvested at that point, whereas others were allowed to recover for 2 h in 10% FBS and then harvested.
RNA extraction
Cells for RNA extraction were about 90% confluent, fresh medium added 8-12 h before the RNA extraction. Total RNA was extracted from fresh cell pellets using RNeasy mini RNA extraction kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions.
RNA amplification, labeling and microarray hybridization and scanning RNAs from two control lines (control 1 and control 3), lines FH-2 and FH-3 and MELAS were used for the expression microarray procedure. RNA integrity was first verified by an Agilent Bioanalyzer. Only high-quality samples were amplified and labeled using standard protocols recommended by Affymetrix (Agilent, Santa Clara, CA, USA), starting from 5 mg of total RNA.
Labeled cRNA was hybridized into GeneChip HG-U133 Plus 2.0 arrays (Affymetrix; Agilent), and incubated overnight at 60 1C with rotation. Arrays were washed and stained using Affymetrix reagents according to the manufacturer's protocol. The arrays were then scanned using an Affymetrix scanner, and the data were normalized to 1.0 and scaled to 100 with GCOS Software (Affymetrix; Agilent). GCOS software was also used to determine if each transcript was present, absent or marginal in each sample, using the algorithm implemented in GCOS with standard parameters. The average P percentage was 38.9% (ranging from 31.1 to 43.9%).
Microarray data analysis
The data were normalized according to a modification of the robust microarray analysis (RMA) procedure, GC-RMA (Irizarry et al., 2003) using commercial software (GeneSpring; Agilent). For fibroblasts, two RNA samples were collected independently from each cell line and each sample was analysed in two separate array experiments (sample replicates). For FH lines we had two biological replicates (FH-2 and FH-3), and for MELAS one patient line. Transcripts with significantly different expression on different experimental conditions were determined based on: (1) uni-caudal Student's t-test and (2) with the ratio of normalized signal intensity between several samples/conditions (for example, fold change). In all data sets, we accepted for further analysis those transcripts that were scored as present at least in two samples (that is, there was statistically significant evidence for hybridization) based on Affymetrix MAS 5.0 algorithm in at least two samples for each data set, and whose expression was statistically significantly different (Po0.05) between FH (or MELAS) and the control fibroblasts. In addition, we selected those transcripts that had at least 1.5-fold change in at least three out of four possible comparisons between FH and control samples, regardless of the result of the statistical test. Maximally four replicates per each phenotype were available, which limited the use of statistical tools. To minimize the possibility of false positives in the analysis, we performed thorough confirmation of the expression levels of several transcripts, both up-and downregulated with both large and small fold-change values, by Q-PCR to assess the technical quality of the results. We also decided to focus on groups of transcripts that are known to be functionally related (transcriptional networks and pathways) rather than individual genes, reducing the effect of single false positives to our results, as the probability of having a substantial number of false positives within one pathway is low. For the uterine data sets, in which the number of samples was appropriate for statistical testing, the cutoff of Po0.05 (uni-caudal Student's t-test) between each type of the leiomyomas and the myometrium was used.
The transcripts that filled the inclusion criteria were then subjected to gene classification, using a databank based on hand-curated literature mining for specific protein-protein interactions and regulatory networks (Ingenuity Pathway Analysis; Ingenuity Systems, Redwood City, CA, USA). The general biological pathways implicated for the significantly changed transcripts by Ingenuity Pathway Analysis were evaluated and P-values o0.05 were considered significant. Further, specific functional networks based on published knowledge on protein-protein interactions and regulatory networks were constructed by Ingenuity Pathway Analysis. After determining networks that were significantly affected, we verified that the transcripts suggested by the software were truly functionally related and correctly annotated. We also verified that the changes observed had directional consistency, that is, pathway elements changing in the same direction, or in a functionally relevant way (for example, gene A induced and repressor of A downregulated), as much as it was possible to interpret from the available literature.
Clustering trees
Clustering trees were constructed using unsupervised hierarchical clustering (GeneSpring; Agilent), using distance as measure of similarity (Eisen et al., 1998) .
Quantitative PCR
Total RNA was extracted from fresh cell pellets using RNeasy mini RNA extraction kit (Qiagen GmbH), according to the manufacturer's instructions. cDNA synthesis and real-time amplification were performed using standardized Assays-onDemand probes (Applied Biosystems; Foster City, CA, USA) as previously described (Raimundo et al., 2008) . The expression of each transcript was normalized to the expression of GAPDH.
Antibodies
Mouse monoclonal antibodies were used against SRF (Upstate Biotechnology; Lake Placid, New York, NY, USA) and FOS (Novus Biologicals; Littletin, CO, USA). Rabbit polyclonal antibodies were used against MAT-1 (Santa Cruz Biotech; Santa Cruz, CA, USA), and SRF-P (Ser-103) (Cell Signalling Technology; Danvers, MA, USA). Secondary antibodies horseradish-peroxidase-conjugated goat anti-mouse and goat anti-rabbit were purchased from Molecular Probes (Invitrogen, Carlsbad, CA, USA).
Preparation of nuclear extracts
Nuclear extracts were prepared according to Wang and Semenza (1995) and modified as in Raimundo et al. (2008) .
Gel electrophoresis and western blotting
Whole-cell extracts, mitochondrial extracts or nuclear extracts were resolved by SDS-polyacrylamide gel electrophoresis on 10% Tris-Glycine gels, under reducing conditions, as previously described (Raimundo et al., 2008) .
Immunohistochemistry Sections (4 mm) of formalin-fixed, paraffin-embedded myomectomy-derived samples of leiomyomas and myometrium from FH patients and sporadic leiomyoma were cut on charged slides. The samples were deparaffinized with xylene and rehydrated in decreasing alcohol concentrations according to standard procedures. Heat-induced epitope retrieval was performed in Tris-HCl buffer, pH 8.5, in a microwave oven for 20 min. The primary phospho-SRF (Ser-103) rabbit polyclonal antibody was diluted 1:100 with Dako REAL Antibody Diluent (Dako Denmark, Glostrup, Denmark). As a negative control we used rabbit IgG (Vectastain) in 1:500 or 1:100 dilutions. The primary antibody (1:500) was incubated on slides for 60 min at room temperature, and secondary antibody (1:5000 anti-mouse, 1:5000 anti-rabbit) with peroxidase labeled polymer reagent (DakoCytomation Reagent Kit þ Dual Link System-HRP DAB þ ; Dako Denmark) for 30 min at room temperature, following the instructions of the kit manufacturer, followed by substrate-DAB incubation for 12 min at room temperature. Counterstaining was performed with hematoxylin for 1 min, according to standard procedures.
Statistical analysis
Data obtained from each patient fibroblast line were compared to those from pooled control fibroblasts using the uni-caudal Student's t-test for populations with unequal variance. P-values under 0.05 were considered significant. Statistical analysis of the microarray analysis is described above, in Microarray data analysis section.
